Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

739
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
739
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

664
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
664
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

478
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
478
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

397
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
397
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

2.6K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.6K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

4.6K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours.

Frontiers in immunology·2026
Same author

Perspectives on caregiver-reported outcomes in cardiovascular diseases today and in future healthcare services: a statement of Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), the Heart Failure Association (HFA), ESC Council on Stroke, and Global Heart Hub, the International Alliance of Heart Patient Organisations.

European journal of cardiovascular nursing·2026
Same author

Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort.

Journal of the American Heart Association·2026
Same author

Identification of Biomarkers for Predicting New-Onset Atrial Fibrillation: A Systematic Review and Meta-Analysis.

European journal of preventive cardiology·2026
Same author

The 'Atrial Fibrillation Better Care' Pathway for Integrated Care of Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Thrombosis and haemostasis·2026
Same author

Nature-based interventions reduce physiological stress in children with chronic illnesses: evidence from salivary biomarkers.

Frontiers in public health·2025

Related Experiment Video

Updated: Feb 5, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K

Chronic Kidney Disease and Third-Generation P2Y

Antonio Tello-Montoliu1, Juan Miguel Ruiz-Nodar2, María Asunción Esteve-Pastor1

  • 1Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain.

Journal of Clinical Pharmacology
|September 13, 2018
PubMed
Summary

Patients with chronic kidney disease (CKD) and acute coronary syndrome (ACS) have worse outcomes. Novel P2Y12 inhibitors improved outcomes in non-CKD patients, but not significantly in CKD patients, without increasing bleeding risk.

Keywords:
acute coronary syndromeantiplatelet agentshemorrhageischemiaplatelet aggregation inhibitorsrenal function

More Related Videos

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.4K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.6K

Related Experiment Videos

Last Updated: Feb 5, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.4K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.6K

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Chronic kidney disease (CKD) is linked to poorer outcomes in acute coronary syndrome (ACS) patients.
  • CKD patients are often underrepresented in clinical trials, limiting understanding of optimal treatments.
  • Novel P2Y12 receptor inhibitors represent a therapeutic advancement in ACS management.

Purpose of the Study:

  • To compare the prognosis of ACS patients with and without CKD.
  • To evaluate the effectiveness and safety of novel P2Y12 receptor inhibitors in ACS patients with and without CKD.
  • To assess the impact of CKD on the outcomes of ACS patients treated with P2Y12 inhibitors.

Main Methods:

  • A multicenter registry study involving 1280 ACS patients from 3 tertiary institutions.
  • Exclusion of anticoagulated patients and those on antiplatelet monotherapy.
  • 1-year follow-up assessing major adverse cardiovascular events, bleeding (BARC classification), and mortality.

Main Results:

  • 25.4% of patients had CKD. Novel P2Y12 inhibitors were used less in CKD patients (22.7%) than non-CKD patients (55.5%).
  • In CKD patients, novel P2Y12 inhibitors showed a non-significant trend towards lower mortality and thrombotic events compared to clopidogrel.
  • Non-CKD patients on novel P2Y12 inhibitors had significantly better outcomes (MACE, all-cause mortality) and lower severe bleeding events compared to clopidogrel. Bleeding risk was not increased in either group with third-generation P2Y12 inhibitors.

Conclusions:

  • Third-generation P2Y12 inhibitors are associated with improved outcomes in non-CKD ACS patients.
  • The benefits of third-generation P2Y12 inhibitors on mortality and thrombotic events were not statistically significant in CKD patients.
  • Third-generation P2Y12 inhibitors appear safe, with no increased bleeding risk in ACS patients regardless of CKD status.